Tirzepatide

tirzepatide (tirzepatide) is a novel glucagon-like peptide-1 receptor (GLP-1) and glucose-dependent insulin-stimulating polypeptide (GIP, also known as gastric inhibitory polypeptide) double-receptor agonist administered once a week. Both GLP-1 and GIP belong to incretin, which is a polypeptide secreted by the human gastrointestinal mucosa. The former can bind to the receptors on the islet cells and stimulate insulin secretion, thus producing hypoglycemic effect, delaying gastric emptying and suppressing appetite, thus controlling body weight. The latter has the function of inhibiting gastric acid, pepsin secretion, stimulating insulin release, inhibiting gastric peristalsis and emptying, and can supplement the effect of GLP-1 receptor agonist. tirzepatide combines the effects of two insulin-promoting drugs into a single molecule and represents a new class of drugs for the treatment of type 2 diabetes.